CASI Pharmaceuticals Faces Nasdaq Delisting
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 25 2026
0mins
Source: seekingalpha
CASI Pharmaceuticals' stock fell significantly as it crossed below the 5-day SMA, reflecting investor concerns.
The company received a determination letter from Nasdaq regarding its delisting due to failure to meet continued listing requirements, with trading expected to be suspended on February 26, 2026. CASI has decided not to appeal this decision, indicating management's resignation regarding its financial situation. Following delisting, CASI's shares are expected to be quoted on the OTC market, which may impact investor liquidity and confidence.
This delisting notice highlights ongoing financial and operational difficulties for CASI Pharmaceuticals, raising concerns about its future financing capabilities and market competitiveness.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
